About KEYMED BIO-B Company

Connoa Biomedical Technology Co., Ltd. is a biotechnology company with multiple clinical-stage assets, each of which is a strong competitor in its own competitive field. We focus on independently discovering and developing innovative biotherapeutics to meet a large number of unmet medical needs in the field of autoimmunity and oncology treatment. With a strong foundation in biomedical research, we have mastered in-house drug discovery and development techniques, including those that make up our innovative antibody discovery platform and our own novel T-cell redirection (NTcE) bispecific antibody platform. In less than five years since our establishment, we have consistently explored the extremely challenging field of disease treatment that is in short supply. We now have more than ten drug candidates in in-house development, five of which are in the clinical phase. Our own products, which are currently being developed, apply cutting-edge scientific findings and reflect our deep market insight. Driven by economic growth and health-care system reforms, health-care spending increased significantly in the first two decades of the new millennium. Due to rapid urbanization, changes in residents' lifestyles, and environmental changes, China's epidemiological focus is shifting from the prevalence of infectious diseases to the prevalence of cancer and other chronic diseases. These basic and evolving trends present new challenges to public health and reveal new areas of disease that place a heavy burden on society due to inadequate treatment options. To support our innovative biopharmaceutical research and development efforts, we have established a comprehensive integrated platform covering all key functions of biopharmaceutical development, including target validation, lead compound generation and optimization, preclinical evaluation, process development, translational research, clinical development and production. This integrated platform enables us to rapidly and cost-effectively discover, build, expand and advance our diverse pipeline of innovative and differentiated antibody therapies, including monoclonal antibodies, antibody-conjugated drugs, and bispecific antibodies.